Antioxidant composition

FIELD: chemistry.

SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.

EFFECT: invention ensures an increase of the antioxidant effect of the composition.

4 cl, 5 dwg, 31 ex

 

The technical field to which the invention relates

The present invention relates to an antioxidant composition that contains one or more compounds selected from the group consisting of D-aspartic acid, its derivatives and/or salts, method of alleviating the condition of the skin, including the stage of introduction of the connection, and the method of treatment and/or prevention of cataracts, including the stage of introduction of the connection.

The level of technology

Reactive oxygen species (ROS) selectivity oxidize biologically active substances, such nucleic acids, proteins and lipids, causing the disruption of a living body or structure of the body and tissues. It is known that ROS are the cause of skin diseases such as skin cancer, skin allergies, skin inflammation and photosensitive dermatitis (non-patent document 1). It is also known that, affecting the epidermis, they cause skin like fine wrinkles, rough skin, dry skin and such.

The documents of the prior art

Non-patent document 1: Bickers, D. R. and Athar, M., Invest. Dermatolog., 126:2565 (2006)

The description of the present invention

The problem to be addressed by the present invention

Ascorbic acid (vitamin C), alpha tocopherol (vitamin E) or similar traditionally used in cosmetic products farmacevticheskom product as antioxidant composition. However, the stability is insufficient and, therefore, there is a need to develop stable and safe composition that can be applied regularly.

The solution to this problem

In this regard, the present invention provides a composition comprising one or more compounds selected from the group consisting of D - and/or L-aspartic acid, their derivatives and/or salts.

Antioxidant composition of the present invention can be applied to inhibit and/or facilitate a skin condition.

Regarding the antioxidant compositions of the present invention is a skin condition includes, but is not limited to, fine lines, rough skin, dry skin, skin cancer, skin allergies, skin inflammation and the photosensitive dermatosis.

Antioxidant composition of the present invention can be applied to a preparation for external application for skin.

Antioxidant composition of the present invention can be used in food.

Antioxidant composition of the present invention can be applied to a pharmaceutical product for cataract.

Regarding the antioxidant compositions of the present invention, a pharmaceutical product for cataract may be a therapeutic agent for cataract or preventive agent for cataract.

ntioxidant composition of the present invention can be used for eye drops for cataracts.

Cataracts can be a senile cataract.

The present invention provides a method of alleviating the condition of the skin, including the stage of introduction of an antioxidant composition consisting of one or more compounds selected from the group consisting of D - and/or L-aspartic acid, their derivatives and/or salts.

The condition of the skin, which inhibit and/or facilitate the method of the present invention, includes, but is not limited to, fine lines, rough skin, dry skin, skin cancer, skin allergies, skin inflammation and the photosensitive dermatosis.

Regarding the method of the present invention antioxidant composition of the present invention can be applied to the preparation for external use on the skin.

Regarding the method of the present invention antioxidant composition of the present invention can be applied to the food composition.

The present invention also provides a method of treatment and/or prevention of cataracts, including the stage of introducing a composition comprising one or more compounds selected from the group consisting of D - and/or L-aspartic acid, their derivatives and/or salts.

Regarding the method of treatment and/or prevention of cataracts of the present invention, a pharmaceutical product for cataract can be a eye drops.

Regarding the method of treatment and/or prevention of cataract present invention cataract may be a senile cataract.

As used in the present description, the term "salt" aspartic acid refers to any salt including a metal salt, amine salt and the like, provided that the antioxidant effect of aspartic acid is not weakened. Salt of the metal may include a salt of an alkaline metal salt, alkaline earth metal and the like. Amine salt may include salt, triethylamine salt of benzylamine and the like.

As used in the present description, the term "derivative" denotes aspartic acid molecule of aspartic acid, which is covalently connected with any group of atoms through its amino group, carboxyl group or a side chain, provided that the antioxidant effect of aspartic acid is not weakened. The group of atoms includes, but is not limited to, a protective group, such as N-phenylacetylene group and 4,4'-dimethoxytrityl (DMT) group, a biopolymer such as a protein, peptide, saccharide, lipid, and nucleic acid; a synthetic polymer, such as polystyrene, polyethylene, polyvinyl and polyester; and a functional group such as ether group. The ether group may include, for example, a complex aliphatic ether, such as methyl ester and the complex is tilby ether, and complex aromatic ether.

The amino acid has optical isomers, which are L-form and D-form. Natural protein contains L-amino acids connected by peptide bonds, and can be applied only L-amino acids, except for some cases, such as bacterial cell wall. Therefore, it is considered that at a mammal, including humans, there are only L-amino acids and apply only L-amino acids (Kinouchi, T. et al., TANPAKUSHITSU KAKUSAN KOSO (PROTEIN, NUCLEIC ACID AND ENZYME), 50:453-460 (2005), Lehninger Principles of Biochemistry [Vol.1] 2nd ed., p.132-147 (1993), Japanese-language translation, Hirokawa Shoten Ltd., Harper's Biochemistry, Original version, 22nd ed., p. 21-30 (1991), Japanese-language translation Maruzen Co., Ltd.). Accordingly, for a long time as amino acids are mostly used for academic and industrial only L-amino acids.

Exceptional case) when using D-amino acid is, for example, the case of application of the crude substances for the antibiotics produced by the microorganism, and the case of dietary supplements, using D-amino acid in DL-amino acid mixture, with the aim of reducing the cost allocation only L-amino acids from a mixture of L - and D-amino acids, which are equimolar quantities of the synthesis of amino acids. However, there are no cases of industrial use only D-amino acid as a bioactive substance.

Detected, D-aspartic acid is localized in the testis or the pineal gland, and known, she participates in the regulation of hormonal secretion (unexamined Japanese patent publication No. 2005-3558). However, the physiological activity of D-aspartic acid in the skin is not precisely known.

As shown in the following examples, it is still unknown whether L - and D-aspartic acid to suppress oxidative damage. Thus, the antioxidant composition containing L - and/or D-aspartic acid, according to the present invention is a new invention.

Recently, it was reported that ddY mice were given free 10 mm aqueous solution of D-amino acids for two weeks and then examined for the concentration of D-amino acids in each organ, which was 3-1000 pmol on the pituitary gland in the pineal gland and 2-500 nmol per gram of fluid in the brain tissue (Morikawa, A. et al., Amino Acids, 32:13-20 (2007)). Based on this, the lower limit of the amount of daily consumption of L - and D-aspartic acids, which are contained in the composition of the present invention, calculated as described below.

Aspartic acid of the present invention affects the suppression of oxidative damage in cultured human cells at concentrations of 0.1 μm (micromolar) - 10 μm (micromolar), as shown in the following examples.

Thus, the number of aspartic acid, which is contained in the agent to facilitate with the standing of the skin, the preparation for external use on the skin and nutritional composition of the present invention, can be any number, provided that the aspartic acid in the above concentration range is distributed in the cells of fibroblasts in skin tissue of a living organism.

When the composition of the present invention is a preparation for external use, the content of aspartic acid can be a 0,000015% by weight to 50% by weight, or up to the maximum weight concentration, which can be formulated on the total amount of the composition of the present invention. Specifically, when the composition is a preparation for external use, the content of aspartic acid is preferably 0,00003% by weight to 30% by weight and most preferably 0,0003% by weight - 3% by weight. When the composition of the present invention is a tool for external use, the content of aspartic acid can be within 0.00001% by weight to 100% by weight. When the composition of the present invention is a tool for external use, the content of aspartic acid is preferably 0,00002% by weight to 80% by weight and most preferably is 0.0002% by weight to 60% by weight. In addition, the lower limit of the amount of daily consumption of D-asparagine the th acid, which is contained in the composition of the present invention, may be of 0.01 ng, preferably 0.1 ng, and more preferably 1 ng per 1 kg of body weight. The lower limit of the amount of daily consumption of L-aspartic acid, which is contained in the composition of the present invention, is an amount that is less than the usual dose of commercially available drugs (20 mg per 1 kg body weight), such as 0.01 mg, preferably 0.1 mg and more preferably 1 mg per 1 kg of body weight.

The composition of the present invention can optionally contain, in addition to free aspartic acid, salt of aspartic acid and/or a derivative thereof, is capable of releasing aspartic acid enzyme metabolizing the drug, and the like in vivo, one or more pharmaceutically acceptable additives, provided that the antioxidant effect of aspartic acid on oxidative damage is not disturbed. Such an additive includes, but is not limited to, a diluent and a filler, binder and adhesive, lubricant, glidant, plasticizer, baking powder, a solvent, which is a carrier, buffer agent, a colorant, a flavoring, a sweetener, a preservative and a stabilizer, the adsorbent, as well as other pharmaceutical additives known to specialists in this region the STI technique.

The composition of the present invention can be obtained using as the active ingredient aspartic acid, salts of aspartic acid and/or derivatives capable of releasing aspartic acid enzyme metabolizing the drug, and the like in vivo. However, within the range in which the effect on oxidative damage of the present invention is not weakened, it can accordingly be formulated with other components, which are used for the preparation for external use on the skin such as cosmetics, including curative and preventive cosmetics and pharmaceutical products, if necessary. Examples of other ingredients (i.e. entered in the optional components include oil, surface-active agent, detergent, dye, water, alcohols, thickening agent, a chelating agent, a silicone, an antioxidant, a means of absorbing UV light, moisturizing agent, flavor, different pharmaceutically active agent, a preservative agent, regulating pH and neutralizing agent.

Dosage form of the antioxidant compositions of the present invention, which is used to inhibit and/or facilitate a condition of the skin (in the present invention below referred to as "a means to facilitate skin condition") may be any dosage form that is usually used for the composition for the treatment and prevention of cosmetic and pharmaceutical compositions containing a preparation for external application for skin, this ointment, cream, emulsion, lotion, compress, gel and plaster; and oral drug that is similar to the powder, granules, soft capsule and tablet; medication for nasal application, such nasal spray; and solution.

Dosage form of the preparation for external use according to the present invention is not specifically limited, provided that it is usually applied as a preparation for external application for skin, and it includes ointment, cream, emulsion, lotion, pack, gel and patch.

Food composition of the present invention can optionally contain, in addition to aspartic acid, salts of aspartic acid and/or derivatives capable of releasing aspartic acid enzyme metabolizing drugs, and the like in vivo, flavouring, colouring agents, preservatives and other components that can be applied to the food product, provided that the effect of aspartic acid on oxidative damage is not weakened.

Food composition of the present invention may be any food composition, commonly used as a food composition, including, but not limited to, candies, biscuits, beans, pasta, French dressing, mayonnaise, French bread, soy sauce, yogurt, dried Orasac-condiment for rice, pripraveny sauce/sauce for soy cheese (Japanese fermented soybeans), soy cheese, unrefined black vinegar.

It is known that ROS is not only the disease of the skin, but also cataracts. Believe that they not only violate the lipid structure of the synthesis of lipid peroxides of polyunsaturated fatty acids on the outside of the lens of the eye due to the recovery of hydrogen peroxide and free radical chain reactions, but also impair membrane function by denaturirovannyj proteins, which ultimately causes a clouding of the crystalline lens. ("SUISHOTAI SONO SEIKAGAKUTEKI KIKO (BIOCHEMICAL MECHANISM OF CRYSTALLINE LENS", p.318-323, by Maesato Takami and Iwata Shuzo, edited by Iwata Shuzo, published by Medical-Aoi Publications, Inc., Tokyo (1986)). According to the results obtained above and the examples described below, the D - and/or L-aspartic acid with anticyclically activity, is effective for prophylaxis or treatment of cataract.

Brief description of drawings

FIG. 1 is a graph showing the effect of carnosine on oxidative damage caused by hydrogen peroxide, normal fibroblastic the human skin cells.

FIG. 2 is a graph showing the effect of L-aspartic acid on oxidative damage caused by hydrogen peroxide, normal fibroblastic the human skin cells.

FIG. 3 is a gr the FIC, showing the effect of D-aspartic acid on oxidative damage caused by hydrogen peroxide, normal fibroblastic the human skin cells.

FIG. 4 is a graph showing the effect of carnosine on oxidative damage AAPH in normal fibroblastic the human skin cells.

FIG. 5 is a graph showing the effect of L - and D-aspartic acids on oxidative damage AAPH in normal fibroblastic the human skin cells.

Description of embodiments of the invention

It is assumed that the examples of the present invention described below only illustrate the present invention and do not limit the technical scope. The technical scope of the present invention is limited only by the description in the claims.

Example 1

The experiment to evaluate the antioxidant effect

1. The purpose of the study

ROS include active forms of oxygen in the narrow sense, including superoxide anion, hydroxyl radical, hydroperoxide and singlet oxygen and reactive oxygen species in a broad sense, including alkoxy radical, hydroperoxyl radical, peroxide radical, hydroperoxide and oxygen complex with the transition metal and the like. Among ROS hydroxyl radical has the largest oxidizing activity of the Yu, but has a very short lifetime. In this regard, he selectivity oxidizes an integral part of the body tissues, like nucleic acids, proteins and lipids, which are present near the place of his generation. However, peroxyl radical has weak oxidizing activity, but it is relatively stable. In this regard, it can diffuse and cause damage to the cell membrane via a free radical chain reaction of polyunsaturated fatty acids. Meanwhile, hydroxyl radical generates peroxyl radical, but hydroxyl radical is generated from the peroxyl radical. Because the mechanism of action is different for hydroxyl radical and peroxyl radical, an effective antioxidant may also be different for each of them. For these reasons, in these examples, the antioxidant effect was evaluated for hydrogen peroxide, and for dihydrochloride salt 2,2'-azobis(2-amidinopropane) (referred to in the present invention below AAPH), which is typical examples of compounds which can generate hydroxyl radical and peroxyl radical, respectively. As a positive control was used carnosine with known antioxidant activity.

2. Materials and methods

2-1. Cells

To assess antioxidant is th effect on the hydrogen peroxide human neonatal fibroblast skin cells (trade name: Cryo NHDF-Neo, received Sankyo Junyaku Co., Ltd.) were seeded in 24-well plate to obtain 1 × 105cells per well. Then cells were cultured for four hours in the medium for cell culture (trade name: D-MEM (1 g/l glucose) obtained Wako Pure Chemical Industries), supplemented with 10% fetal bovine serum (referred to in the present invention "standard environment") in 5% CO2and in an atmosphere of saturated water vapor at 37°C (degrees Celsius). To evaluate the antioxidant effect on AAPH antibiotics (penicillin, streptomycin and Fungizone) was added to the standard medium, and cells were cultured for one day.

2-2. Environment for evaluation of antioxidant effect

Then the culture medium was replaced with medium for cell culture (trade name: D-MEM (1 g/l glucose) obtained Wako Pure Chemicals Industries) with 0.5% of bovine fetal serum (referred to in the present invention "medium with low serum"), to which was added at 0.01% or 0.05% carnosine, or 0.1 μm (micromolar), or 10 μm (micromolar) D - or L-aspartic acid, and cells were cultured for two days in an atmosphere of 5% CO2and saturated humidity at 37°C (degrees Celsius). For the experiments on the evaluation of oxidative damage on AAPH culture medium was replaced by medium for cell culture, to which was further added ág/g 100 ág/g of carnosine or 10 μm (micromolar) D - or L-aspartic acid, and cells were cultured for two days. The medium containing a low concentration of serum, as described above, to which was added or carnosine, or aspartic acid, was used as a negative control.

2-3. Adding developer

After culturing for two days, 1 mm or 4 mm hydrogen peroxide, or 50 mm, or 100 mm AAPH was added to the medium for the evaluation of antioxidant effect and antioxidant effect was evaluated for the production of carnosine or aspartic acid. The medium containing a low concentration of serum, as described above, to which was added or carnosine, or aspartic acid, was used as a control to assess the toxicity of antioxidant without addition of an oxidant.

2-4. Quantification of oxidative damage

Two hours after addition of hydrogen peroxide or AAPH AlarmarBlue (trade name: Biosource received Biosource International Inc.) added receiving a final concentration of 10%. After 2-3 hours, according to the ways Ahmed S. A. et al. (J. Immunol. Method., 170, 211-224 (1994)) and the instructions provided by the manufacturer, the intensity of the conditioned medium was measured with a wavelength of excitation 544 nm and emission wavelength of 590 nm.

3. Results

3-1. Antioxidant effect of carnosine on the hydrogen peroxide

Figure 1 shows the results of the experiment, half the military study of the antioxidant effect of carnosine on the hydrogen peroxide in Cryo NHDF-Neo cells. Trims error for each condition of the experiment show the standard deviation of the experimentally measured values, obtained by repeating three times the experiment under identical conditions. The asterisk (*) shows that t is less than 5% Bonferroni/Dunn test.

The ratio of viable cells for the control group to assess the toxicity of antioxidant without addition of an oxidant was 102% without adding carnosine. When the concentration of carnosine was to 0.01%, the ratio was 100%. When the concentration of carnosine was 0.05%, the ratio was 97%. The ratio of viable cells in the case of adding 1 mm hydrogen peroxide was 45% without the addition of carnosine. When the concentration of carnosine was to 0.01%, the ratio was 51%. When the concentration of carnosine was 0.05%, the ratio was 53%. The ratio of viable cells in the case of 4 mm hydrogen peroxide was 14% without the addition of carnosine. When the concentration of carnosine was to 0.01%, the ratio was 21%. When the concentration of carnosine was 0.05%, the ratio was 45%. Thus, when the hydrogen peroxide concentration was 4 mm, observed a significant difference in the ratio of viable cells for the case, which was added 0.05% of carnosine, compared with the ratio without adding carnosine. Based on the above results, the effect of carnosine on Perek the camping hydrogen was confirmed in the experimental system of this example.

3-2. Antioxidant effect of L-aspartic acid to hydrogen peroxide

Figure 2 shows the experimental results obtained by the study of the antioxidant effect of L-aspartic acid to hydrogen peroxide in Cryo NHDF-Neo cells. Trims error for each condition of the experiment show the standard deviation of the experimentally measured values, obtained by repeating three times the experiment under identical conditions.

The ratio of viable cells for the control group to assess the toxicity of antioxidant without addition of an oxidant was 93% without the addition of L-aspartic acid. When the concentration of L-aspartic acid was 0.1 μm (micromolar), it was 88%. When the concentration of L-aspartic acid was 10 μm (micromolar), it was 97%. The ratio of viable cells in the case of 1 mm hydrogen peroxide was 61% without the addition of L-aspartic acid. When the concentration of L-aspartic acid was 0.1 μm (micromolar), it was 62%. When the concentration of L-aspartic acid was 10 μm (micromolar), it was 62%. The ratio of viable cells in the case of 4 mm hydrogen peroxide was 36% without the addition of L-aspartic acid. When the concentration of L-aspartic acid was 0.1 μm (micromolar), it was 33%. When the concentration L acid was 10 μm (micromolar), it was 32%. Based on the above results, a statistically significant antioxidant effect of L-aspartic acid to hydrogen peroxide was observed.

3-3. Antioxidant effects of D-aspartic acid to hydrogen peroxide

Figure 3 shows the experimental results obtained by the study of the antioxidant effect of D-aspartic acid on oxidative damage caused by hydrogen peroxide in Cryo NHDF-Neo cells. Trims error for each condition of the experiment show the standard deviation of the experimentally measured values, obtained by repeating three times the experiment under identical conditions. The asterisk (*) indicates that p is less than 5% Bonferroni/Dunn test. A double asterisk (**) indicates that p is less than 1% Bonferroni/Dunn test.

The ratio of viable cells for the control group to assess the toxicity of antioxidant without addition of an oxidant was 97% without the addition of D-aspartic acid. When the concentration of D-aspartic acid was 0.1 μm (micromolar), it was 86%. When the concentration of D-aspartic acid was 10 μm (micromolar), it was 97%. In the case of 1 mm hydrogen peroxide, the ratio of viable cells was 55% without the addition of D-aspartic acid. When the concentration of D-aspartic acid was 0.1 m is M (micromolar), it was 62%. When the concentration of D-aspartic acid was 10 μm (micromolar), it was 63%. In the case of 4 mm hydrogen peroxide, the ratio of viable cells was 22% without the addition of D-aspartic acid. When the concentration of D-aspartic acid was 0.1 μm (micromolar), it was 29%. When the concentration of D-aspartic acid was 10 μm (micromolar), it was 34%. Thus, when the hydrogen peroxide concentration was 4 mm, observed a significant difference between the relationship of viable cells for the case, which was added to 0.1 μm (micromolar) or 10 μm (micromolar) D-aspartic acid, compared with the ratio without the addition of D-aspartic acid. Based on the above results, it was observed depending on the concentration of the antioxidant effects of D-aspartic acid on hydrogen peroxide.

3-4. Antioxidant effect of carnosine in the experiment to evaluate the oxidative damage induced by AAPH

Figure 4 shows the experiment obtained by the study of the antioxidant effect of carnosine in the experiment for the assessment of oxidative damage caused by AAPH in Cryo NHDF-Neo cells. Trims error for each condition of the experiment show the standard deviation of the experimentally measured values, obtained by repeating three times the experiment is ω in identical conditions. A double asterisk (**) indicates that p is less than 1% Bonferroni/Dunn test.

The ratio of viable cells for the control group to assess the toxicity of antioxidant without addition of an oxidant was 100% without adding carnosine. When the carnosine concentration was 5 µg/g, it was 93%. When the carnosine concentration was 100 µg/g, it was 103%. The ratio of viable cells in 100 mm AAPH was 31% without the addition of carnosine. When the carnosine concentration was 5 µg/g, it was 60%. When the carnosine concentration was 100 µg/g, it was 85%. When AAPH has a concentration of 100 mm, was observed a marked difference between the attitudes of viable cells for the case in which added carnosine at a concentration of 100 µg/g, compared with the ratio without adding carnosine. Based on the above results, the effect of carnosine on AAPH was confirmed by the experimental system is presented.

3-5. Antioxidant effect of L - and D-aspartic acids in the experiment for evaluating the oxidative damage induced by AAPH

Figure 5 shows the experiment obtained by the study of the antioxidant effect of L - and D-aspartic acids in the experiment for evaluating the oxidative damage induced by AAPH in Cryo NHDF-Neo cells. Trims error for each condition of the experiment show the standard from which Lonnie experimentally measured values, received repeated three times experiment under identical conditions. The asterisk (*) indicates that p is less than 5% Bonferroni/Dunn test. A triple asterisk (***) indicates that p is less than 0.1% Bonferroni/Dunn test.

The ratio of viable cells for the control group to assess the toxicity of antioxidant without addition of an oxidant was 95% without the addition of L - and D-aspartic acids. When the concentration of D-aspartic acid was 10 μm (micromolar), it was 102%. When the concentration of L-aspartic acid was 10 μm (micromolar), it was 80%. In the case of 100 mm AAPH, the ratio of viable cells was 51% without the addition of L - and D-aspartic acids. When the concentration of D-aspartic acid was 10 μm (micromolar), it was 96%. When the concentration of L-aspartic acid was 10 μm (micromolar), it was 69%. When AAPH has a concentration of 100 mm, was observed a marked difference between the attitudes of viable cells for the case, which was added L - and D-aspartic acid at a concentration of 10 μm (micromolar), compared with the ratio without the addition of L - and D-aspartic acids. Based on the above results, it was shown that D-aspartic acid has stronger antioxidant effect on AAPH compared with L-aspartic acid

4. Conclusions

On the basis of the scientific research Institute of experimental results of the above examples, it was found that D-aspartic acid has an antioxidant effect on the hydrogen peroxide and AAPH. However, it was found that L-aspartic acid has antioxidant effect only on AAPH. Thus, it was shown that D-aspartic acid is an effective and relatively hydroxyl radical, peroxyl radical, but L-aspartic acid is effective only with respect peroxyl radical.

Example 2

Examples of the compositions containing aspartic acid, according to the present invention, namely, the drug-based emulsion, patch, tablet, soft capsule, granule, drink, candy, biscuits, beans, pasta, French dressing, mayonnaise, French bread, soy sauce, yogurt, dry powder seasoning for rice, spice/sauce for soy cheese, soy cheese, unrefined black vinegar, cream, body cream, gel, exfoliating mask, moisturizing mask, emulsion, lotion for the skin and the drug-based aerosol below. Aspartic acid in the sample composition is a or D-form and/or L-form.

All these examples of compositions are illustrative and are not intended to restrict the technical scope of the present invention.

Example composition 1 (drug-based emulsion)

(Composition)The content (% by weight)
Aspartic acid0,42
Beganovic alcohol0,2
The latter0,5
Monoether fatty acids and glycerol1,8
Hydrogenated castor oil POE (60)1,0
White petrolatum2,0
Liquid paraffin10,0
Isopropylmyristate3,0
Methylpolysiloxanes (6cs)1,5
Concentrated glycerin13,0
Dipropyleneglycol2,0
Carboxyvinyl polymer0,25
Sodium hyaluronate0,005
Potassium hydroxidean appropriate number
Lactic acidan appropriate number
Edetate sodiuman appropriate number
Ethylparabenan appropriate number
Purified waterbalance
100,000

Example of compound 2 (patch)

(Composition)The content (% by weight)
Aspartic acid0,3
Polyacrylic acid3,0

Polyacrylate sodium2,5
Gelatin0,5
Carboxymethylcellulose sodium4,0
Polyvinyl alcohol:0,3
Concentrated glycerin14,0
1,3-Butyleneglycol12,0
Aluminum hydroxide0,1
Edetate sodium0,03
Methylparaben0,1
Purified waterbalance
100,00

Example of compound 3 (pill)

(Composition)Content (mg/tablet)
Aspartic acid360,5
Lactose102,4
Carboxymethylcellulose calcium29,9
Hydroxypropylcellulose6,8
Magnesium stearate5,2
Crystalline cellulose10,2
515,0

Example of compound 4 (pill)

(Composition)Content mg/pill)
The sucrose esters70
Crystalline cellulose74
The methylcellulose36
Glycerin25

Aspartic acid475
N-Acetylglucosamine200
Hyaluronic acid150
Vitamin E30
Vitamin B620
Vitamin B210
α(alpha)-lipoic acid20
Coenzyme Q1040
Ceramide (extract cognac)50
L-Proline300
1500

Example of compound 5 (soft capsule)

(Composition)Content (mg/capsule)
Food soybean oil530
Extract eucommia iloveny50
Ginseng extract50
Aspartic acid100
Royal jelly50
Poppy30
GABA30
Beeswax60
Gelatin375
Glycerin120
Ester of fatty acid and glycerol105
1500

Example of compound 6 (soft capsule)

td align="justify"> Aspartic acid
(Composition)Content (mg/capsule)
Oil from seeds brown rice659
500
Resveratrol1
The extract from the seeds of the Lotus100
Elastin180
DNA30
Folic acid30
1500

Example of compound 7 (pellet)

(Composition)Content (mg/packing)
Aspartic acid400
Vitamin C100
Soybean isoflavone250
Restored lactose300
Soy oligosaccharide36
Erythritol36
Dextrin30
Flavor24
Citric acid24
1200

Example of compound 8 (drink)

(Composition)Content (g/60 ml)
Extract eucommia iloveny1,6
Ginseng extract1,6

α(alpha)-lipoic acid
Aspartic acid0,25
Restored maltose syrup28
Erythritol8
Citric acid2
Flavor1,3
N-Acetylglucosamine1
Sodium hyaluronate0,5
Vitamin E0,3
Vitamin B60,2
Vitamin B20,1
0,2
Coenzyme Q101,2
Ceramide (extract cognac)0,4
L-Proline2
Purified waterbalance
60

Example of compound 9 (candy)

(Composition)The content (% by weight)
Sugar50
Syrup48
Aspartic acid1
Flavor1
100

Example of compound 10 (biscuits)

(Composition)The content (% by weight)
Non-germinating flour45,0

Oilof 17.5
Crystal sugar20,0
Aspartic acid4,0
Egg12,5
Flavor1,0
100,0

The method of obtaining the composition of example 10 (biscuits)

Granulated sugar is added in portions to the oil under stirring, to which is added, mix the egg, aspartic acid and flavoring. After thorough mixing evenly add not viable sifted flour and mix at low speed and leave in the form of mass in the refrigerator. After that she gives shape and baked for 15 minutes at 170°C (degrees Celsius) to get the cookie.

Example of compound 11 (bean paste)

(Composition)Content (g)
Soybeans1000
Malt rice1000
Sol420
Aspartic acid16,8
Waterbalance
4000

The method of obtaining the composition of example 11 (bean paste)

Malt rice thoroughly mixed with the salt. Washed soy beans soaked over night in three volumes of water, which is then strained into a bowl, and add new water during boiling and pour in colander to collect broth (solution tanimizu), in which dissolve aspartic acid at 10% weight/volume. Boiled beans immediately crushed, mixed with rice malt, mixed with salt, to which is added the solution tanimizu containing dissolved therein aspartic acid, and uniformly stirred to obtain a solid substance such as clay. Get dumplings and put them together in a container so that it does not contain voids, and surface content smooth and sealed with plastic film. After three months, the contents transferred to a new container and the surface is smooth and sealed with plastic film. Instead of adding aspartic acid to the solution tanimizu you can use rice malt, providing a large number of aspartic acid. Malt rice can be selected quantitative definition is of aspartic acid method, described in Japanese unexamined patent publication No. 2008-185558. Alternative to commercially available bean paste, you can add aspartic acid or its salt.

Example of compound 12 (French dressing)

(Composition)Content (g)
Vegetable oil27,4
Vinegar30,4
Sodium chloride0,9
Aspartic acid0,30
Pepper1,0
60,0

The method of obtaining the composition of example 12 (French dressing)

Vinegar mixed with sodium chloride and aspartic acid, and then thoroughly stirred to dissolve. Add to the mix the vegetable oil, the mixture was mixed thoroughly and then add the pepper.

Example of compound 13 (Mayonnaise)

(Composition)Content (g)
Vegetable oil 134,0
Vinegar5,5
Sodium chloride0,9
Aspartic acid0,5
Egg yolk18
Sugar0,2
Pepper0,9
160,0

The method of obtaining the composition of example 13 (Mayonnaise)

Egg yolk (room temperature) is mixed with vinegar, sodium chloride, aspartic acid, and pepper and mix thoroughly, using the apparatus for whipping. Stirring is continued while adding portions of vegetable oil to obtain the emulsion. Finally, add the sugar and the mixture is stirred.

Example of compound 14 (French bread)

(Composition)Content (g)
Baking flour140
Non-germinating flour60

Sodium chloride3
Sugar6
Aspartic acid2
Dry yeast4
Warm water128
343

The method of obtaining the composition of example 14 (French bread)

Warm water mixed with 1 g of sugar and dry yeast, which is then subjected to preliminary fermentation. Baking flour, non-germinating flour, sodium chloride, 5 g of sugar and aspartic acid are placed in the pelvis, in which was placed a pre-fermented yeast, thoroughly mix to obtain a test, conduct primary fermentation at 30°C (degrees Celsius). The dough again mix and leave, and then give it the desired shape, which is subjected to the final fermentation, using an electronic machine for fermentation. After shaping the baking is carried out for 30 minutes in an oven at 220°C (degrees Celsius).

Example of compound 15 (soy sauce)

(Composition)Content (g)
And is audica on sale soy sauce 995,8
Aspartic acid4,2
1000

The method of obtaining the composition of example 15 (soy sauce)

To commercially available soy sauce add aspartic acid and mix thoroughly. Instead of aspartic acid or its salts can be used rice malt, giving a large amount of aspartic acid to the fermentation of soy sauce. This malt rice can be selected quantitative determination of aspartic acid by the method described in Japanese unexamined patent publication No. 2008-185558. Next, aspartic acid or its salt can be added to commercially available soy sauce.

Example 16 (Yogurt)

(Composition)Content (g)
Milk880
L. bulgaricus50
S. thermophilus50
Aspartic acid20
1000

Pic is b obtain the composition of example 16 (Yogurt)

The fermentation is carried out at 40-45°C (degrees Celsius). You can use other commercially available organisms carrying out the fermentation, and other commercially available yogurt you can add aspartic acid. Instead of adding aspartic acid or its salts can be used organism for fermentation, producing a large number of aspartic acid. This body, you can choose the quantitative determination of aspartic acid by the method described in Japanese unexamined patent publication No. 2008-185558. Next, aspartic acid or its salt can be added to commercially available yogurt.

Example of compound 17 (dry powder seasoning to rice)

(Composition)Content (g)
Aspartic acid50
Red algae15
L-monosodium glutamate10
Sodium chloride2
Roasted sesame10
The dry powder of mackerel10
Sugar1
Soy sauce2
100

Example of compound 18 (seasoning sauce for soy cheese)

(Composition)Content (g)
Commercially available sauce for soy cheese9,96
Aspartic acid0,04
10

Example of compound 19 (Soy cheese)

(Composition)Content (g)
Commercially available soy cheeseto 19.9
Aspartic acid0,1
20

The method of obtaining the composition of example 19 (soy cheese)

Instead of adding aspartic acid or its salt, soy cheese, you can apply the body, producing a large number of aspartic acid. This body, you can choose the number of the defective determination of aspartic acid method, described in Japanese unexamined patent publication No. 2008-185558. Next, aspartic acid or its salt can be added to commercially available soy cheese.

Example of compound 20 (unrefined black vinegar)

(Composition)Content (g)
Commercially available unrefined black vinegar995,8
Aspartic acid4,2
1000

The method of obtaining the composition of example 20 (unrefined black vinegar)

Instead of adding aspartic acid or a salt thereof to obtain vinegar, black vinegar or raw vinegar can be applied to the body, producing a large number of aspartic acid. This body, you can choose the quantitative determination of aspartic acid by the method described in Japanese unexamined patent publication No. 2008-185558. Next, aspartic acid or its salt can be added to commercially available unrefined black vinegar.

Example of compound 21 (cream)

(Composition)Soda is the content (%)
Liquid paraffin3
White petrolatum1
Dimethylpolysiloxane1
Stearyl alcohol1,8
Beganovic alcohol1,6
Glycerin8
Dipropyleneglycol5

Oil macadamia nut2
Hydrogenated oil3
Squalane6
Stearic acid2
Cholesterolcholesterol0,5
Cetyl 2-ethylhexanoate4
Polyoxyethylene hydrogenated castor oil0,5
Self emulsifiable glycerylmonostearate 3
The potassium hydroxide0,15
The sodium hexametaphosphate0,05
Trimethylglycine2
Ascorbylpalmitate sodium1
Tocopherylacetate0,1
Aspartic acid0,42
Parabenan appropriate number
Edetate trisodium0,05
4-tert-butyl-4'-methoxydibenzoylmethane0,05
Glyceriloleatecocoate0,05
Dyean appropriate number
Carboxyvinyl polymer0,05
Purified waterbalance
100,00

Example of compound 22 (body cream)

(Composition)Content (%)
Dimethylpolysiloxane3

Decamethylcyclopentasiloxane13
Dodecamethylcyclohexasiloxane12
Policyactioninpolicyrule copolymer1
Ethanol2
Isopropanol1
Glycerin3
Dipropyleneglycol5
Polyethylene glycol 60005
The sodium hexametaphosphate0,05
Tocopherol acetate0,1
Aspartic acid0,3
Extract of fennel (fennel)0,1
Extract of Hamamelis Virginia (Le is in Virginia) 0,1
Ginseng extract0,1
L-mentholan appropriate number
Broadcast peroxybenzoyl acid (paraben)an appropriate number
Edetate trisodium0,05
Disorganization0,01
Isobutyltrimethoxysilane0,1
Iron oxide yellowan appropriate number
The titanium oxide-cobaltan appropriate number
Dimethyltitanocene ammonium1,5

Polyvinyl alcohol:0,1
Hydroxyethylcellulose0,1
Trimethylsulfoxonium2
Flavoran appropriate number
Purified waterbalance
100,00

Example of compound 23 (gel)

(Composition)Content (%)
Dimethylpolysiloxane5
Glycerin2
1,3-Butyleneglycol5
Polyethylene glycol 15003
The polyethylene glycol 200003
Tetracylcine3
Citric acid0,01
Sodium citrate0,1
The sodium hexametaphosphate0,1
Glycyrhiza of dItalia0,1
Aspartic acid0,4
Tocopherylacetate0,1
Extract from the roots of Scutellaria baicalensis0,1
Extract of saxifrage0,1
Edetate trisodium0,1
Xanthan gum0,3

Acrylates/C10-30 alkylacrylate cross-linked polymer (pemulen TR-2)0,05
Powdered agar1,5
Phenoxyethanolan appropriate number
Purified waterbalance
100,00

Example of compound 24 (exfoliation)

(Composition)Composition (%)
Ethanol10
1,3-butyleneglycol6
Polyethylene glycol 40002
Olive oil1
Oil macadamia nut1
Finasteridefinasteride acid0,05
Lactic acid0,05
Sodium lactate0,1
Ascorbylpalmitate disodium0,1
Ascorbylpalmitate potassium0,1
Aspartic acid0,3
Fish collagen0,1
Chondroitin sulfate sodium0,1
Carboxymethylcellulose sodium0,2
Polyvinyl alcohol:12
Aired phenoxybenzoic acid (Paraben)an appropriate number
Flavoran appropriate number
Purified waterbalance

100,00

Example of compound 25 (hydrating mask)

(Composition)Content (%)
Glycerin1
1,3-Butyleneglycol8
Xylitol2
Polietilenglikolya 15002
Rosemary0,01
Sage oil0,1
Citric acid0,02
Sodium citrate0,08
The sodium hexametaphosphate0,01
Hydroxypropyl-β(beta)-cyclodextrin0,1
Aspartic acid0,2
Extract of birch0,1
Lavender oil0,01
Xanthan gum0,05
Carboxyvinyl polymer0,15
Broadcast peroxybenzoyl acid (paraben)an appropriate number
Purified waterbalance
100,00

Example of compound 26 (emulsion)

(Composition)Content (%)
Liquid paraffin7
White petrolatum3

Decamethylcyclopentasiloxane2
Beganovic alcohol1,5
Glycerin5
Dipropyleneglycol7
Polyethylene glycol 15002
Jojoba oil1
Izote Renova acid 0,5
Stearic acid0,5
Beginilah acid0,5
Pentaerythritol(2-ethylhexanoate)3
Cetyl 2-ethylhexanoate3
Glycerol monostearate1
Polyoxyethylene-glycerol monostearate1
The potassium hydroxide0,1
The sodium hexametaphosphate0,05
Sterillization0,05
Aspartic acid0,3
Royal jelly extract0,1
Extract from yeast0,1
Tocopherol acetate0,1
Atsilirovannye sodium hyaluronate0,1
Edetate trisodium 0,05
4-tert-butyl-4'-methoxydibenzoylmethane0,1
2-ethylhexylacrylate0,1
Carboxyvinyl polymer0,15
Parabenan appropriate number

Flavoran appropriate number
Purified waterbalance
100,00

Example of compound 27 (emulsion)

(Composition)Content (%)
Dimethylpolysiloxane2
Beganovic alcohol1
Batrawy alcohol0,5
Glycerin5
1,3-Butyleneglycol7
Erythritol 2
Hydrogenated oil3
Squalane6
Pentaerythritol(2-ethylhexanoate)2
Polyoxyethylenesorbitan1
Poliauxietilenglikola1
Aspartic acid0,3
The potassium hydroxidean appropriate number
The sodium hexametaphosphate0,05
Phenoxyethanolan appropriate number
Carboxyvinyl polymer0,1
Purified waterbalance
100,00

Example of compound 28 (skin lotion)

(Composition)Content (%)
Ethanol 5

Glycerin1
1,3-Butyleneglycol5
Polyoxyethylene-Polyoxypropylenediamine ether0,2
The sodium hexametaphosphate0,03
Trimethylglycine1
Polyasparaginic sodium0,1
Ascorbylpalmitate potassium0,1
Thiotaurine0,1
Aspartic acid0,2
Edetate trisodium0,1
Carboxyvinyl polymer0,05
The potassium hydroxide0,02
Phenoxyethanolan appropriate number
Flavoran appropriate number
Cleaned the water output balance
100,00

Example of compound 29 (skin lotion)

(Composition)Content (%)
Ethanol10
Dipropyleneglycol1
Polyethylene glycol 10001
Polyoxyethyleneglycol1
Jojoba oil0,01
Glyceryl three(2-ethylhexanoate)0,1

Polyoxyethylene hydrogenated castor oil0,2
Polyglycerylmethacrylate0,15
N-steroyl-L-glutamate sodium0,1
Citric acid0,05
Sodium citrate0,2
potassium Hydroxide 0,4
Glycyrhiza of dItalia0,1
Arginine hydrochloride0,1
L-Ascorbic acid 2-glycoside2
Aspartic acid0,2
Edetate trisodium0,05
Octyl 4-methoxycinnamate0,01
Dibutylaminoethanolan appropriate number
Parabenan appropriate number
Sea water from a great depth3
Flavoran appropriate number
Purified waterbalance
100,00

Example of compound 30 (stock solution of the aerosol preparation of urea-based for external use)

(Composition) The content (% by weight)
Ethanol15,0
Polyoxyethylene hydrogenated castor oil 501,5
Diphenhydramine1,0

The dibucaine2,0
Tocopherylacetate0,5
Aspartic acid0,1
Ezoterikova acid0,1
1,3-Butyleneglycol3,0
The polyethylene glycol 4003,0
Camphor0,05
Urea20,0
Purified waterbalance
100,00

Example of compound 31 (aerosol spray urea-based)

(Composition)
Stock solution of the aerosol preparation of urea-based for external use65,0
Dimethyl ether35,0
100,00

The method of obtaining the composition of example 31 (aerosol spray urea-based)

Stock solution of the aerosol preparation of urea-based for external use and dimethyl ether filled in resistant aluminum pressure tank for spray, the inner surface of which is coated with Teflon (registered trademark), to obtain the aerosol product.

1. Antioxidant composition for suppression of oxidative damage to the skin, containing one or more compounds selected from the group consisting of D-aspartic acid, its derivatives and/or salts.

2. Antioxidant composition under item 1, where the specified composition is used to inhibit and/or facilitate a skin condition.

3. Antioxidant composition under item 2, where the skin condition is selected from the group consisting of fine lines, wrinkles, rough skin, dry skin, skin cancer, skin allergies, skin inflammation and photosensitive dermatosis.

4. Antioxidant composition according to any one of paragraphs.1-3, where the specified composition ol the change in the quality of the preparation for external use on the skin.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to the field of preparations for the oral cavity care and methods of their application. The composition for the oral cavity care contains from 0.6 wt % to 1 wt % of arginine in a D- or L-form or in the form of salt with lauroylsulphuric acid, at least one mucoadhesive polymer, at least one pyrophosphate compound and, at least one component, selected from the group, consisting of zinc salts, potassium salts, strontium salts and their mixtures. The method of realising one or more of the effects, selected from the group, consisting of the reduction of the teeth hypersensitivity; reduction or inhibition of dental caries formation; reduction or inhibition of demineralisation and contribution to the teeth remineralisation; reduction or inhibition of gingivitis; inhibition of a microbial biofilm formation in the oral cavity; reduction of dental plaque accumulation; treatment of the mouth dryness; reduction of the teeth erosion; protection of enamel after an erosive impact; and cleaning and/or whitening teeth and cleaning the oral cavity, includes the application of the said composition in the oral cavity. The product consists of a packing material and the claimed composition, with the packing material containing a label, which indicates that the oral composition is effective with respect to the reduction or prevention of dentin hypersensitivity.

EFFECT: group of inventions provides successful realisation of an internal blockage of dentinal canals, simultaneously providing the antibacterial and/or anti-caries efficiency.

19 cl, 4 tbl, 2 ex

Tooth paste // 2535051

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to oral hygiene products. The presented tooth paste comprises lysine, papaine, dextranase, alpha amylase, glucoamynase, superoxide dismutase, glucose oxydase, lactoperoxidase or peroxidise, invertase, cytochrome-c-oxidase, as well as sphagnum or cedar extract, dipotassium glycyrizinate, potassium thiocyanate, sodium-calcium salt of poly(methyl vinyl ether-co-maleic acid), betaine, DL-pyrrolidone carboxylate N-cocoyl ethyl arginate and sodium fluoride, a polymer thickener, an emulsifier, a flavouring agent, sorbitol 70%, demineralised water.

EFFECT: tooth paste composition provides the effective oral cleansing and tooth deposit removal with using no abrasives, reducing oral angiostaxis and inflammations, and also promotes remineralising dental enamel.

4 cl, 11 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: formulation of initial ingredients of the presented tooth paste for treating and preventing dento-facial inflammatory diseases involves a tissue regeneration stimulator specified in hyaluronic acid or sucralfate, or ε-acetylaminocapronic acid sodium salt, the enzymes lysozyme, papaine and hyaluronidase, as well as an abrasive ingredient, a moistening agent, hydrocolloid, a surfactant, sodium fluoride, tetrapotassium pyrophosphate, a preserving agent, a flavouring agent and water in certain amounts.

EFFECT: effective oral cleaning and removal of plaque, reduced bleeding gum and oral inflammations, faster dento-facial regeneration in the inflammations.

4 cl, 9 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to oral care compositions and methods for using them. The presented composition contains 15 to 35 wt % of glycerol; 17 to 45 wt % of propylene glycol; 15 to 35 wt % of sorbitol and less than 10 wt % of water and possesses a relatively high antimicrobial activity, characterized by a load test result calculated as a normalized area under curve (NAUC) making 65-75 or more. The composition is free from anion surfactants and a fluoride ion source. A version of the composition contains glycerol in an amount of 20 to 24 wt %, approximately 25 wt % of propylene glycol, approximately 23 wt % of sorbitol and additionally approximately 0.1 wt % of citric acid. What is also presented is a method of treating or preventing oral diseases involving contacting a patient's oral surface with any of the versions of the above composition.

EFFECT: using the above amounts of glycerol, propylene glycol and sorbitol in a combination with the amount of water limiter to less than 10 wt % enables providing an adequately high level of the antimicrobial activity of the oral care composition in the absence of such ingredients as anion surfactants and a fluoride ion source that in turn enables avoiding side effects caused by these ingredients.

12 cl, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and represents a composition adapted for oral administration, able to provide an anti-ageing skin effect, and containing the PPAR ligand containing omega-3 fatty acid specified in DHA, EPA or mixtures thereof, an agent binding to an oestrogen receptor, containing soya isoflavones, taking part in the post-translation collagen modification, representing vitamin C and a carotinoid; the composition contains one or more additional ingredients specified in antioxidants, flavouring agents, preserving agents and stabilising agents; the composition is substantially free from zinc and/or selenium, the composition is presented in the form of a capsule; provided the composition contains at least 0.01 wt % edible phospholipid emulsifying agents, a total amount of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in the composition makes more than 0.6 wt % or less than 0.024 wt %.

EFFECT: invention provides the synergetic effect on procollagen I, thereby ensuring the better positive anti-ageing skin effect.

13 cl, 2 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pharmacy, and concerns developing medical dental pencils containing calcium gluconate, and can be used in integrated treatment of the oral diseases related to calcium deficiency. The dental pencil contains a mechanically active amorphous or amorphous crystalline calcium salt of gluconic acid as an active substance, contains paraffin, Vaseline oil, Tween 80, low-molecular polyethylene (LMPE), Lutrol 127 in the following proportions, g per 1 pencil, taken as a base: mechanically active amorphous or amorphous crystalline calcium salt of gluconic acid - 0.4; paraffin - 0.4, Vaseline oil 0.4, Tween 80 - 0.6, -molecular polyethylene (LMPE) - 2.0, Lutrol 127 - 0.02. As a preserving agent, the dental pencil additionally contains benzoic acid - 0.0008 g.

EFFECT: presented dental pencils possess the high therapeutic activity, provides the uniform release of the active substances, the evident prolonged action and unassisted usability.

3 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention represents a natural antioxidant preparation technology for cosmetic applications. The presented method for preparing a biologically active extract of grape berries or secondary wine making products - husks of grapes - provides drying the raw material, grinding, mixing it with an extactant in a ratio of 1:2.

EFFECT: method provides producing the all-purpose antioxidant for all types of cosmetics rich in biologically active substances with the relatively simple technological process requiring no organic acids used.

1 cl, 2 ex, 1 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: oral and dental care wipe comprises a hydrophilic cloth base and a therapeutic agent in the form of a bonding agent containing a composition of eucalyptus, mint, thyme and anise essential oils, an aqueous suspension of propolis dissolved in an aqueous solution of glycerol in the following proportions, wt %: eucalyptus 0.5-2; mint 1-20; thyme 1-3; anise 1-20, aqueous suspension of propolis 1-20; water with glycerol in equal proportions - the rest.

EFFECT: using the wipe promotes eliminating the pathogenic microflora, has the anti-inflammatory, repairing, deodorant and whitening effects.

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an oral care composition and to a method for using the above composition for treating or preventing the dental calculus formation. The presented composition contains an anticalculous agent and an antibacterial agent containing a biphenol compound, which can be prepared of Magnolia officinalis; wherein the above composition is free from phosphate-containing anticalculous agents and polyphosphate-containing anticalculous agents; and wherein the anticalculous agents contain zinc oxide as a zinc ion source. The method of treating or preventing the dental calculus formation involves contacting the above composition with the oral cavity. What is also presented is a method for preventing the inhibition of the magnolia antibacterial agent absorption in the oral cavity from the above composition free from the polyphosphate-containing anticalculous agents or polyphosphate-containing anticalculous agents.

EFFECT: using the magnolia antibacterial agent in a combination with the anticalculous agents containing zinc oxide provides the improved absorption of the above antibacterial agent in the oral cavity in the absence of the polyphosphate-containing anticalculous agents or polyphosphate-containing anticalculous agents.

8 cl, 8 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: described are compositions for hair care, containing a β-aminoether compound in a cosmetically acceptable carrier, such as a spray or cream. Described is a compound of formula

:

in which n represents an integer number from 1 to 100; Z and Z′ together with atoms, which they are bound to, represent acrylate, methacrylate or amino-terminal groups; R2 represents C1-C20alkyl, possibly substituted with: hydroxyl, siloxyl, C1-C20alkoxygroup, substituted with hydroxyl, amino-C1-C20alkyl, substituted with from one to two hydroxyl groups, C6-C10aryl, substituted with C1-C20alkoxygroup, or C5-C10heteroaryl, containing one nitrogen heteroatom; and A contains a rubber fragment, which has a molecular weight in the range from approximately 1000 g/mol to approximately 10000 g/mol, selected from the group, consisting of butadiene and isoprene units. Also described is a cosmetic composition for hair, containing the said compound and cosmetically acceptable carrier. The application of the said cosmetic composition for scalp care is described.

EFFECT: obtaining the cosmetic composition for hair, increasing adhesion of hairs to each other, adding volume, texture and shape to the hair.

10 cl, 4 tbl, 17 ex

FIELD: medicine.

SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.

EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.

EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.

8 cl, 2 ex, 2 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.

EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.

7 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, particularly to method of treatment of dermatological allergic state. Proposed method comprises injection of efficient amount of [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-silt][7-fluorine-1-(2-metoxyethyl)-4-trifluorometoxy-1H-indol-3-il]methanon or its appropriate N-oxide, pharmaceutically acceptable salt or solvate.

EFFECT: higher efficiency.

5 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to an agent for preventing and/or treating an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma, which is a low-molecular polysulphated hyaluronic acid derivative.

EFFECT: obtaining a low-molecular polysulphated hyaluronic acid derivative.

15 cl, 103 dwg, 17 tbl, 55 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns preparing a fast-acting effective and safe agent for treating rhinitis. Solving the problem provides the agent for treating rhinitis, particularly allergi rhinitis containing C-type natriuretic peptide (CNP) and/or B-type natriuretic peptide (BNP) as an active ingredient.

EFFECT: invention provides the notable health improvement in rhinitis, particularly in allergic rhinitis, and besides, the therapeutic effect, ensures fast and prolonged action, and gives no local side effects.

21 cl, 7 ex, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using a composition containing galactooligosaccharide, fructooligosaccharide and uronic acid oligosaccharide in preparing a composition for oral administration into an infant for preventing the local administration of corticosteroids and/or preventing the administration of a calcineurin inhibitor into the above infant, wherein uronic acid oligosaccharide represents a pectin degradation product and/or an alginate degradation product, and wherein using the corticosteroids and/or administering the calcineurin inhibitor is applicable for treating eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Particularly, the composition is a nutritional composition.

EFFECT: what is shown is reducing probability of the local administration of corticosteroids and dermatological preparations to be required for the purpose of preventing the above skin diseases, or reducing the length of using the corticosteroids.

5 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to naphthalene carboxamide derivatives of general formula I which possess the properties of protein kinase or histone deacetylase inhibitors. The compounds can find application for preparing a drug for treating inflammatory diseases, autoimmune diseases, oncological disease, diseases of the nervous system and neurodegenerative diseases, allergies, asthma, cardiovascular diseases and metabolic diseases or disease related to hormonal diseases. In general formula I: , Z represents CH or N; each of the groups R1, R2 and R3 represents hydrogen, halogen, alkyl, alkoxy or trifluoromethyl; R4 represents or X represents a benzene ring or a pyridine ring; R5 represents one or more substitutes specified in a group consisting of hydrogen, halogen, alkyl, alkoxy or trifluoromethyl. The invention also refers to a method for preparing the above compounds, a pharmaceutical preparation and using them.

EFFECT: preparing the compounds which possess the properties of protein kinase or histone deacetylase inhibitors.

13 cl, 10 tbl, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a complex of biologically active substance for treating allergic diseases of various genesis, characterised by the fact that it has been recovered from cod liver oil by gradual fractionation from ballast lipids by extraction in a two-phase oil and water extractant, centrifugation and ultrafiltration or diafiltration through a material with separation limit 25 kDa, and contains peptides 30-55%, amino acids 40-65%, carbohydrates 2-8%, micro and macroelements 2-13%.

EFFECT: invention provides the drug spectrum broadening.

8 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel of 2,4-pyrimidine diamine compounds of formula I, which inhibit degranulation of immune cells and can be used in treating cell reactions mediated by FcεRI or FcγRl receptors. In formula (I) each R2 and R4 is independently phenyl substituted with one or more R8 groups or a heteroaryl selected from a group consisting of , where the heteroaryl is optionally substituted with one or more R8 groups and at least one of R2 and R4 is a heteroaryl; R5 is selected from a group consisting of (C1-C6)alkyl, optionally substituted with one or more identical or different R8 groups, -ORd, -SRd, fluorine, (C1-C3)halogenalkyloxy, (C1-C3)perhalogenalkyloxy, -NRcRc, (C1-C3)halogenalkyl, -CN, -NO2, -C(O)Rd, -C(O)ORd, -C(O)NRcRc, -C(NH)NRcRc, -OC(O)Rd, -OC(O)ORd, -OC(O)NRcRc; -OC(NH)NRcRc, - [NHC(O)]nORd, R35 is hydrogen or R8; each Y is independently selected from a group consisting of O, S and NH; each Y1 is independently selected from a group consisting of O, S and NH; each Y2 is independently selected from a group consisting of CH, CH2, S, N, NH and NR37. Other values of radicals are given in the claim.

EFFECT: improved efficiency.

19 cl, 6 tbl.

FIELD: chemistry.

SUBSTANCE: claimed is method of obtaining photosensibiliser, which consists in the following: 3-pyridylcarboxaldehide is condensed with pyrrole in mixture propionic acid-propionic anhydride with their ratio 3-4:1-2 in boiling for 80-100 min. product of condensation is reduced with p-toluenesulfonylhydrazide in pyridine medium in presence of potassium carbonate with its 30-35-fold excess and 5-10% quinoline at temperature 85-95°C for 4-5 hours. After that, obtained product is N-methylated in dimethylformamide in boiling for 50-65 min, precipitated with benzene, filtered and dried. Also claimed is photosensibiliser, obtained in accordance with claimed method, which contains 5,10,15,20-tetrakis(N-methyl-3'-pyridyl)chlorine in quantity 15-25% and 5,10,15,20-tetrakis(N-methyl-3'-pyrydyl)bacteriochlorine in quantity 75-85%.

EFFECT: increase of target product output, reduction of tumour growth rate and dissemination, prevention of tumout tissue necrotisation, complete and uniform saturation of tumour tissue with medication.

3 cl, 1 dwg, 1 tbl, 2 ex

Up!